Frederick Kahn, MD
Pulmonary Disease · Billings, MTNPI 1942295134
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $715 and has fallen 84.0% since, to $114 in 2025.
Across 53 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$216
- Kerecis Limited$185
- AstraZeneca$130
- Hydrofera LLC$129
- Integra Lifesciences Corporation$120
- Bristol Myers Squibb$120
- plus $547 from 14 others
Across 3 payments — averaging $11,342 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$34K
What the payments were for
- Food & beverage$1,35694%
- Education$906%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $216 |
| Kerecis Limited | 2 | $185 |
| AstraZeneca | 10 | $130 |
| Hydrofera LLC | 1 | $129 |
| Integra Lifesciences Corporation | 3 | $120 |
| Bristol Myers Squibb | 1 | $120 |
| Actelion Pharmaceuticals US, Inc. | 5 | $102 |
| Genentech USA, Inc. | 5 | $88 |
| KCI USA, Inc. | 1 | $66 |
| Solventum Corporation | 1 | $63 |
| GSK | 3 | $62 |
| Mimedx Group, Inc. | 1 | $32 |
| Grifols USA, LLC | 2 | $28 |
| Harmony Biosciences LLC | 2 | $27 |
| Sanofi | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Gilead | 1 | $12 |
| Molnlycke Health Care US, LLC | 1 | $12 |
| Vapotherm Inc | 1 | $8 |
| United Therapeutics Corporation | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,446 in reported general payments places this provider in the 70th percentile of 43 pulmonary disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Monohydrate | 41 | $1,114 |
| Clindamycin Hcl | 18 | $425 |
| Levofloxacin | 34 | $324 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $140 |
| Cephalexin | 21 | $116 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Billings
- Fernando CaceresBillings$2K
- Vineeth KumarBillings$2K
- Manfred BaumgartnerBillings$1K
- Aleksandra KwasnikBillings$840
- Andrew FischerBillings$755
- Nicole PhilipsBillings$520
- David PucciBillings$441
- Erin RainsBillings$161
- Randol HooperBillings$70
- Robert MerchantBillings$26
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.